E13-01: Insights into thymic epithelial tumor: pathology  by Müller-Hermelink, Hans Konrad
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS258
CEA, MIB1 index, and BAC component ratio were signiﬁcantly as-
sociated with prognosis. Cases stained strongly with anti-CEA antibody 
showed a signiﬁcantly less favorable outcome than CEA-negative cases 
(p=0.02). Cases with a MIB1 index of 10% or more showed a less fa-
vorable outcome than cases with a MIBI index of less than 10%. Cases 
in which the BAC component accounted for 50% or more of the tumor 
showed a better outcome than cases in which the BAC component ac-
counted for less than 50% (p<0.01). However, none of the other factors 
were related to outcome. Although numerous prognostic factors of lung 
adenocarcinoma have been reported, this study found that only three 
factors, i.e. the two immunohistochemical factors, CEA and MIB1 
index, and the histological factor, the ratio of the BAC component in 
the largest cut surface of the tumor, were signiﬁcantly associated with 
the prognosis of small-sized adenocarcinoma of the lung. 
In order to achieve desirable and evidence-based selective diagnosis of 
small-sized adenocarcinomas that are treatable by reduction surgery, a 
more extensive study to search for convenient prognostic factors should 
be performed. One trial to ﬁnd new prognostic factors for small-sized 
adenocarcinomas, especially replacement-type adenocarcinoma, has 
already been done using two representative cases that were subjected 
to polymerase chain reaction-based cDNA suppression subtractive 
hybridization (SSH) (2). One case was LBAC (type A), which shows 
an extremely favorable prognosis, and the other was LBAC with foci 
of ﬁbroblastic proliferation (type C), which is considered to be an 
invasive adenocarcinoma. Differential screening using virtual reverse 
northern hybridization and quantitative real-time reverse transcrip-
tion-polymerase chain reaction (qRT-PCR) showed that ﬁve genes 
(TncRNA, OCIAD2, ANXA2, TMED4 and LGALS4) were expressed 
at signiﬁcantly higher levels in invasive adenocarcinoma with a BAC 
component (type C) than in LBAC (type A). After in situ hybridiza-
tion and qRT-PCR analyses, the OCIAD2 gene showed signiﬁcantly 
higher expression in the tumor cells of invasive adenocarcinoma than 
in LBAC. The OCIAD2 gene was originally identiﬁed by Strausberg 
et al. in 2002 because of its sequential similarity to ovarian carcinoma 
immunoreactive antigen 1 through the National Institutes of Health 
Mammalian Gene Collection Project. OCIAD2 and OCIAD1 constitute 
the OCIA domain family. OCIAD1 was identiﬁed by Luo et al. in 2001 
by immunoscreening of an ovarian carcinoma cDNA expression library 
with ascites from ovarian cancer patients. The function of OCIAD2 has 
not been elucidated, but the protein may be immunosensitive as an anti-
gen and, like OCIAD1, could be a cancer-speciﬁc protein. Using in situ 
hybridization, the expression of OCIAD2 was examined in 56 replace-
ment-type adenocarcinomas resected at Tsukuba University Hospital 
(Ibaraki, Japan). The patients with OCIAD2 expression showed a better 
clinical outcome than those without OCIAD2 expression, and OCIAD2 
expression showed an inverse correlation with lymphatic invasion, 
blood vessel invasion and lymph node metastasis. These results suggest 
that OCIAD2 begins to be expressed during progression from in situ 
to invasive carcinoma, and is associated with a favorable prognosis of 
invasive adenocarcinoma with a BAC component (type C). 
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The histopathological classiﬁcation of thymic epithelial tumours has for 
a long time been controversial. The great morphologic variability, their 
rareness, and the lack of consistent follow-up data were arguments to 
attribute only minor value to the histopathological descriptive classiﬁ-
cation and to rely on the clinical appearance at surgery almost exclu-
sively for deciding further therapy of prognosis. A major problem for 
the introduction of a new and biology-oriented classiﬁcation was the 
general believe that in spite great morphological variability, prognosis 
would be almost the same and recurrences or metastases could not be 
predicted. Therefore, as a pragmatic approach, the usual categories of 
malignancy, namely benign tumours, low grade malignant and high 
grade malignant tumours in the thymus where classiﬁed at surgery: 
encapsulated, non-invasive tumours as benign thymoma, those with 
minimal atypia (whatever this is) as malignant thymoma type 1, and 
those with marked atypia as thymic carcinoma with increasing invasive 
and metastatic potential (6). Coming from a completely different ap-
proach, namely from the investigation of the complicated epithelial and 
lymphoepithelial structure of the thymus a “histogenetic” classiﬁcation 
has been proposed, comparing the organization of epithelial cells and 
their lymphocyte content to the normal thymic structure in 5 histo-
pathologically deﬁned categories of thymoma, as medullary thymoma, 
mixed thymoma, predominantly cortical thymoma, cortical thymoma, 
and well differentiated thymic carcinoma - and the group of thymic 
carcinomas not presenting organotypic features (5,7). The tumour types 
and their deﬁnitions were accepted as basis of the WHO classiﬁcation 
(1999), but as no agreement could be reached for the naming, the types 
were designed with letters A, B, and C (Table I).
Histogenetic classiﬁcation WHO classiﬁcation Biology
Medullary thymoma A Benign
Mixed thymoma AB Benign
Predominantly cortical thymoma B1 Borderline
Cortical thymoma B2 
Well differentiate thymic carcinoma, malignant, organotypic, usually 
no extra thoracic metastases
Well differentiated thymoma B3 
Thymic carcinomas C Malignant, low grade high grade related to 
subtypes
This classiﬁcation was discussed and updated in the new series of the 
WHO classiﬁcation of tumours pathology and genetics and basically 
conﬁrmed (WHO 2004 , 8). 
Histolopathological classiﬁcation of thymic epithelial tumours
The term thymoma is used for organotypic thymic epithelial tumours, 
characterized by similarities to the structural organization of the normal 
thymus. The histopathological typing is highly predictive for the risk of 
invasiveness, recurrence, and metastases, and for the need of adjuvant 
treatment after surgery. 
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Thymic carcinoma do not or only minimally show organotypic features 
and are classiﬁed and grades as morphologically identical malignant 
epithelial tumours in other organ systems. 
The following table summarizes the main clinical and biological fea-
tures of the different subtypes of thymoma. 
Fig. 1 Frequency of histological thymoma subtypes at the Institute of  
Pathology, Würzburg
Fig. 2 Age and sex distribution of thymoma patients
Fig. 3 Tumour Stage of histological thymoma subtypes
Fig. 4 Association with myasthenia gravis
Type A and type AB thymomas are almost in very case encapsulated 
tumours found in stage 1 or 2 (with invasion of capsule but not cross 
invasion of mediastinal fat of pleura). They are found in a slightly older 
age group than the group of cortical type thymomas type B1, B2, and 
B3. The overall sex distribution is almost equal for male and female pa-
tients, type AB and B1 showing a slight dominance of female patients. 
Type B1, B2, and B3 show increasing invasive potential where type B1 
may be regarded still as benign/borderline, but type B2 and B3 show 
high invasive and metastatic potential at surgery. 
All types of thymoma may be associated with myasthenia gravis. The 
association is signiﬁcantly higher in type B1, B2, and B3. 
Genetic features of different thymoma subtypes
Whereas type A and AB show no or only minimal genetic imbalances at 
comparative genomic hybridization, type B2 and B3 as well as thymic 
carcinomas show very high frequencies of genetic imbalances, which is 
correlated their malignant behaviour. The pattern of genetic imbalances 
is highly characteristic for these tumours and allows the conclusion of a 
genetic relationship of type B and B3 thymoma and thymic carcinoma. 
The most frequent aberrations are found on chromosome 6, where 
homozygous deletions are found even in type A on chromosome 6p 
(involving the MHC locus), loss of heterozygocity and monosomy 6 
involving 6p and 6q of the most frequent genetic changes in thymomas. 
Loss of heterozygocity or uniparental disomy of 6p implies a hemizy-
gous MHC expression and therefore may be related to the increase of 
autoimmune paraneoplastic diseases (2,3,410,,11,12). 
Type B3 thymomas are more heterogeneous. The distribution of genetic 
imbalances hint to two different transformation pathways:
1. 6q23.3-25.3 associated oncogenic transformation and 
2. a transformation pathway with loss of APC, RB, and p53 loci. 
These ﬁndings have recently been conﬁrmed and extended by gene ex-
pression proﬁling studies in thymoma, showing that all ﬁve subtypes of 
thymoma can be deﬁnitely distinguished by unique genetic signatures 
involving different pathways of oncogenic pathways of transformation.
Clinicopathological correlation
A large retrospective analysis of tumour stage at surgery using the Ma-
saoka staging system, the WHO histotype of thymoma, and the surgical 
resectability (R0, R1) deﬁne independent predictive parameters. In this 
large retrospectively analysed cohort of 267 thymic tumours, WHO 
histotype A, AB, and B1 tumours do not show tumour-related death, 
but even B2 and B3 tumours, if complete surgical resection is pos-
sible or performed, the probability of recurrence is low, implying that 
adjuvant treatment by chemotherapy or radiation can be restricted to 
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thymoma types B2, B3, and, of course, thymic carcinoma. In the case 
of thymoma (B2, B3), there is good retrospective evidence that local 
irradiation deﬁnitely reduces the rate of recurrences by 20%. 
In conclusion, WHO type A, AB, and B1 thymoma types do not need 
adjuvant treatment, if surgical resection is complete. WHO type B2 and 
B3, as well as combined tumours and thymic carcinoma proﬁt from ad-
juvant treatment which should at least be directed to local recurrences 
(local irradiation) or imply adjuvant chemotherapy (1,10). No prospec-
tive clinical studies are available. 
Pathogenesis of thymoma-associated autoimmune phenomena
Thymomas are associated to a large variety of autoimmune phenomena 
where myasthenia gravis is the most frequent and classical paraneo-
plastic autoimmune disease. A detailed functional analysis of thymoma 
associated with myasthenia gravis reveals that these tumours produce 
and export autoreactive CD4+ T cells into the periphery (while thymo-
mas not associated to myasthenia gravis do not). A major effect related 
to the generation of autoimmune disease may be attributed to the 
ﬁnding that within these tumours the production of adequate numbers 
of regulatory T cells (CD4+, CD25+) is signiﬁcantly decreased (10,11). 
Further pathogenetic ﬁndings related to thymomas associated myas-
thenia gravis shows that polymorphisms in the co-stimulatory recep-
tor CTLR4 with high expression is found in patients with thymoma 
( 2). Furthermore, the already cited hemizygous expression of MHC 
molecules is deﬁnitely a factors increasing the overall probability of au-
toimmune diseases in these patients. The ﬁndings imply that tumour-as-
sociated intratumourous defects of T cell differentiation are the reason 
for these autoimmune diseases and that different pathogenetic pathways 
may play a role. 
Differential diagnosis of thymic carcinoma
Mediastinal involvement by carcinoma may be derived from different 
primary sites. The differential diagnosis of squamous cell carcinoma 
of thymus vs. lung is the most challenging problem. Some topographic 
and structural features favour a thymic origin:
If the squamous cell carcinoma is adjacent to thymoma or combined 
with thymoma type B3, a thymic origin is very likely. Prominent 
perivascular spaces in the tumour and the overall lobular architecture 
also suggests thymic squamous cell carcinoma (TSCC). Furthermore, 
immunohistochemical ﬁndings may help: thymic squamous cell 
carcinomas often express CD5 and CD70, and may contain myoid 
cells (similar to the normal thymus). The value and sensitivity of CD5 
expression in the most frequent subtype (SCC) is about 60%, but the 
speciﬁcity in squamous cell carcinoma is almost absolute. Another 
highly sensitive and speciﬁc marker is the expression of the c-kit 
tyrosin kinase receptor (CD117). Expression is found In squamous 
cell carcinoma of the thymus in 90% whereas it is seen in pulmonary 
squamous cell carcinoma only in 5% (8). Further differences reside on 
genetic characterization. A typical loss of the long arm of chromosome 
16 (16q-) or the combination of 16q- with deletions on chromosome 6 
or ampliﬁcation of chromosome 18 are highly predictive for a primary 
thymic tumour in comparison to lung or squamous cell carcinoma of 
the upper respiratory track. 
Conclusion
The diagnosis of thymoma and thymic carcinoma is now in a stage 
where an agreed histopathological classiﬁcation is accepted. The rules 
of this classiﬁcation have to be learnt but are highly reproducible in all 
published series. This classiﬁcation will help to elaborate therapeutic 
protocols for prospective clinical studies. The variability of clinical 
presentation and behaviour still requires several clinicopathologic 
correlations. Modern techniques of immunostochemistry, molecular 
techniques and gene expression will improve the diagnosis and open 
new horizons for an indiviualized therapy. 
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Thymic epithelial tumors (TET) are uncommon, with a broad spectrum 
of biologic and morphologic features. Of several proposed classiﬁca-
tions, WHO histologic classiﬁcation reﬂects both the clinical and the 
functional features of TET and thus contributes to the clinical assess-
ment and treatment of patients with these tumors (1, 2). Recently, sev-
eral reports described speciﬁc CT, MR imaging, and FDG-PET features 
of TET that reﬂect the WHO histologic subtypes (3-7). In this section, 
we discuss imaging features of TET correlated with histologic subtypes.
Computed Tomography (CT)
Because of embryologic background and anatomic location, TET can 
occur adjacent to the junction of the great vessels and the pericardium; 
less commonly, in the cardiophrenic angles or adjacent cardiac borders; 
and, rarely in the neck or other mediastinal compartments (8). CT has a 
much higher sensitivity for detecting TET than conventional radiog-
raphy, and also allows evaluation of (a) invasion of the surrounding 
mediastinal fat, vascular structures, and adjacent lung; and (b) the pres-
ence of pleural and extrapleural seeding. On CT scans, TET usually ap-
pear as homogeneous, oval, rounded or lobulated soft-tissue masses in 
the anterior mediastinum (8). In cases of invasive thymoma or thymic 
carcinoma, invasion of the mediastinal fat or adjacent structures as well 
as pleural seeding may be seen.
Tomiyama et al (3) assessed the CT features of various subtypes of 
TET and reported that smooth contours and a round shape are most 
suggestive of type A tumors, irregular contours are most suggestive of 
type C tumors, and calciﬁcation is suggestive of type B tumors. Jeong 
et al (5) reviewed the CT ﬁndings correlated with simpliﬁed WHO 
classiﬁcation of TET (low-risk thymomas (type A, AB, and B1); high-
risk thymomas (type B2 and B3); thymic carcinomas (type C)) and 
prognosis. CT ﬁndings that are more common in high-risk thymomas 
and thymic carcinomas include lobulated contour, mediastinal fat inva-
sion, and great vessel invasion. Findings associated with signiﬁcantly 
more frequent recurrence and metastasis include lobulated or irregular 
contour, oval shape, mediastinal fat invasion or great vessel invasion, 
and pleural seeding. 
